The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment

Publication Citation

Tran TH, Nguyen JV, Stecula A, Akutagawa J, Moorman AV, Braun BS, Sali A, Mullighan CG, Shah NP, Dai Y, Devidas M, Roberts KG, Smith CC, Loh ML. The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment. Haematologica. 2021 Aug 1;106(8):2242-2245. doi: 10.3324/haematol.2020.261354. PubMed PMID: 33626861; PubMed Central PMCID: PMC8327742.

Abstract

No abstract provided.

Link To Publication